- Mingote S, Bruin JPC, Feenstra MGP. Noradrenaline and dopamine efflux in the prefrontal cortex in relation to appetitive classical conditioning. Journal of Neuroscience, 2004; 24(10): 2475-2480. - Mingote S, Weber SM, Ishiwari K, Correa C, Salamone JD. Effort and time requirements of operant schedules influence sensitivity to nucleus accumbens dopamine depletions. European Journal of Neuroscience 2005; 21(6): 1749-1757. - Salamone JD, Correa M, Farrar A, Mingote S. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology, 2007: 191(3): 461-82. - Mingote S, Pereira M, Farrar AM, McLaughlin PJ, Salamone JD. Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacol Biochem Behav, 2008;89:345-351. - Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, Port RG, Sink KS, Bunce JG, Chrobak JJ, Salamone JD. Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. J Neurosci, 2008; 28:9037-9046. - Chuhma N, Choi WY, Mingote S, Rayport S. “Dopamine Neuron Glutamate Cotransmission: Frequency-Dependent Modulation in the Mesoventromedial Projection”. Neuroscience, 2009; 164 (3): 1068-1083. - Gellman C, Mingote S, Wang Y, Gaisler-Salomon I, Rayport S. “Genetic Pharmacotherapy, Drug Discovery and Development - Present and Future”, Dr. Izet Kapetanović (Ed.), 2011. ISBN: 978-953-307-615-7, InTech, Available from: http://www.intechopen.com/books/drug-discovery-and- development-present-and-future/genetic-pharmacotherapy - Chuhma N, Mingote S, Moore H, Rayport S. “Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling.” Neuron, 2014; 81(4): 901-912.